down arrow

Galecto, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US36322Q1076
USD
22.89
3.55 (18.36%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

21.1723.70

52 Week

2.0133.60
Valuation
Technical
Day's Volume

CASH

27.45 k

Shareholding (Mar 2025)

FII

7.68%

Held by 7 FIIs

DII

79.23%

Held by 3 DIIs

Promoter

10.40%

How big is Galecto, Inc.?

22-Jun-2025

As of Jun 18, Galecto, Inc. has a market capitalization of 4.26 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -18.49 million over the latest four quarters. The company reported shareholder's funds of 14.47 million and total assets of 17.13 million as of Dec 24.

Market Cap: As of Jun 18, Galecto, Inc. has a market capitalization of 4.26 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Galecto, Inc. reported net sales of 0.00 million and a net profit of -18.49 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 14.47 million and total assets of 17.13 million.

Read More

What does Galecto, Inc. do?

22-Jun-2025

Galecto, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for fibrosis and related diseases. As of March 2025, it has a market cap of $4.26 million and reported a net profit loss of $3 million.

Overview: <BR>Galecto, Inc. is a clinical-stage biotechnology company focused on developing therapeutics targeting fibrosis and related diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 4.26 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.86 <BR>Return on Equity: -106.34% <BR>Price to Book: 0.34<BR><BR>Contact Details: <BR>Address: Galecto Biotech Ab, Ole Maaloes Vej3, COPENHAGEN DE: DK-2200 <BR>Website: https://galecto.com/

Read More

Is Galecto, Inc. technically bullish or bearish?

20-Sep-2025

As of July 29, 2025, Galecto, Inc. is in a mildly bearish trend with daily moving averages indicating bearish momentum, despite mixed signals from weekly MACD and RSI, and has significantly underperformed the S&P 500 with a year-to-date return of -38.28%.

As of 29 July 2025, the technical trend for Galecto, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven primarily by the daily moving averages indicating a bearish trend. While the weekly MACD shows a mildly bullish signal, the overall indicators such as Bollinger Bands and KST are leaning bearish on both weekly and monthly time frames. The RSI is bullish on a monthly basis but shows no signal weekly, indicating mixed momentum. <BR><BR>In terms of performance, Galecto has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -38.28% compared to the S&P 500's 12.22%, and a one-year return of -79.1% against 17.14% for the index.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 4 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.92

stock-summary
Return on Equity

-126.91%

stock-summary
Price to Book

0.43

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
670.71%
0%
670.71%
6 Months
593.64%
0%
593.64%
1 Year
297.4%
0%
297.4%
2 Years
52.6%
0%
52.6%
3 Years
1415.89%
0%
1415.89%
4 Years
-61.85%
0%
-61.85%
5 Years
-93.63%
0%
-93.63%

Galecto, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Galecto, Inc. technically bullish or bearish?

As of 29 July 2025, the technical trend for Galecto, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven primarily by the daily moving averages indicating a bearish trend. While the weekly MACD shows a mildly bullish signal, the overall indicators such as Bollinger Bands and KST are leaning bearish on both weekly and monthly time frames. The RSI is bullish on a monthly basis but shows no signal weekly, indicating mixed momentum. In terms of performance, Galecto has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -38.28% compared to the S&P 500's 12.22%, and a one-year return of -79.1% against 17.14% for the index....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
14.76%
EBIT to Interest (avg)
-37.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.86
Sales to Capital Employed (avg)
0
Tax Ratio
0.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
24.81%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.35
EV to EBIT
0.45
EV to EBITDA
0.46
EV to Capital Employed
-3.49
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-106.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 7 Schemes (2.7%)

Foreign Institutions

Held by 7 Foreign Institutions (7.68%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 35.85% vs 50.47% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.40",
          "val2": "-4.50",
          "chgp": "24.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-1.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.40",
          "val2": "-5.30",
          "chgp": "35.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 44.13% vs 37.82% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.70",
          "val2": "-35.60",
          "chgp": "53.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.40",
          "val2": "-3.40",
          "chgp": "-58.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.40",
          "val2": "-38.30",
          "chgp": "44.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.40
-4.50
24.44%
Interest
0.00
0.00
Exceptional Items
0.00
-1.00
100.00%
Consolidate Net Profit
-3.40
-5.30
35.85%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 35.85% vs 50.47% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-16.70
-35.60
53.09%
Interest
0.00
0.00
Exceptional Items
-5.40
-3.40
-58.82%
Consolidate Net Profit
-21.40
-38.30
44.13%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 44.13% vs 37.82% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Galecto, Inc. stock-summary
stock-summary
Galecto, Inc.
Pharmaceuticals & Biotechnology
Galecto Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. The Company’s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The Company is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate portfolio also includes GB1211, a selective oral galectin-three inhibitor, which is being developed for the treatment of fibrosis related to non-alcoholic steatohepatitis (NASH), and GB2064, a selective oral inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which fibrosis reduces the ability to form blood cells.
Company Coordinates stock-summary
Company Details
Galecto Biotech Ab, Ole Maaloes Vej3 , COPENHAGEN DE : DK-2200
stock-summary
Tel:
stock-summary
https://galecto.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."